Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Leo Miller

THE TRUTH ABOUT: Nektar jumps 157 on drug trial data can it go even higher - The Untold Story

And two Wall Street analysts believe shares could go even higher.

BTIG Research and HC Wainwright updated their price targets on the stock to $100 and $120, respectively. As of June 24, the MarketBeat-tracked consensus price target on Nektar was around $76, implying 212% upside. However, when taking these two new targets into account, shares could rise by 349%.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.